Payment overview · 2025
General Payments
$3,262.85
136 reported records · 19 companies
Healthcare provider profile · identity verified
Dhanpat Chandra Mohnot, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · GRETNA, LA · NPI 1780689364
Verified facts
What the public records show
CMS Open Payments records show Dhanpat Chandra Mohnot, MD received $3,262.85 in general payments during 2025 across 136 reported records.
ABBVIE INC. accounted for 23.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Briviact, Gocovri, Nurtec Odt, Qulipta, Ubrelvy, Zavzpret.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ubrelvy by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gocovri as an associated drug or biological on 3202 records involving 1029 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Gocovri by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZAVZPRET as an associated drug or biological on 140787 records involving 33518 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Zavzpret by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Austedo by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $753.24 | 23.1% | 42 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $487.75 | 14.9% | 17 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $358.53 | 11.0% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $306.12 | 9.4% | 11 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $222.66 | 6.8% | 26 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $153.80 | 4.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $137.12 | 4.2% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $134.92 | 4.1% | 8 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $125.00 | 3.8% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$107.27 | 3.3% | 2 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $78.08 | 2.4% | 3 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $73.79 | 2.3% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $58.52 | 1.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $56.16 | 1.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $52.01 | 1.6% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $46.77 | 1.4% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $46.02 | 1.4% | 2 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $44.28 | 1.4% | 2 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $20.81 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,224.31 | 135 |
| Education | $38.54 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $537.57 | 35 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $358.53 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $299.61 | 26 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $282.40 | 12 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $244.40 | 27 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $195.44 | 4 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $137.12 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $137.12 | 2 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $134.92 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $130.22 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $107.27 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $102.71 | 6 | 2025 |
Source payment records
|
|||||
| ZEMBRACE SYMTOUCH Normalized: zembrace symtouch |
Drug | Tonix Medicines, Inc. | $73.79 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $58.52 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $56.16 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $46.77 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $46.37 | 5 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $26.70 | 2 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $23.18 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | MDD US Operations, LLC | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $7.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 40 | exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gocovri gocovri |
2025 | Gocovri | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 42 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 60 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 72 | exact normalized | Medicare Part D |
| ZAVZPRET zavzpret |
2025 | Zavzpret | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
40 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
60 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
72 | 19 |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Gocovri open payments reported associated product |
CMS Open Payments — General Payments 3202 supporting records · 1029 recipient NPIs · example record 1241843637 |
Gocovri · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ZAVZPRET open payments reported associated product |
CMS Open Payments — General Payments 140787 supporting records · 33518 recipient NPIs · example record 1228794071 |
Zavzpret · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 573 | 173 |
| Memantine Hcl Er | Memantine Hcl | 305 | 84 |
| Lamotrigine | Lamotrigine | 283 | 58 |
| Donepezil Hcl | Donepezil Hcl | 246 | 70 |
| Sumatriptan Succinate | Sumatriptan Succinate | 204 | 47 |
| Gabapentin | Gabapentin | 186 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 174 | 43 |
| Mirtazapine | Mirtazapine | 170 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 147 | 39 |
| Bupropion Xl | Bupropion Hcl | 137 | 33 |
| Levetiracetam | Levetiracetam | 137 | 34 |
| Amlodipine Besylate | Amlodipine Besylate | 129 | 42 |
| Baclofen | Baclofen | 128 | 35 |
| Divalproex Sodium | Divalproex Sodium | 123 | 41 |
| Topiramate | Topiramate | 120 | 34 |
| Nortriptyline Hcl | Nortriptyline Hcl | 112 | 31 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 109 | 24 |
| Primidone | Primidone | 102 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 101 | 30 |
| Zonisamide | Zonisamide | 100 | 18 |
| Sertraline Hcl | Sertraline Hcl | 97 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 95 | 30 |
| Rivastigmine | Rivastigmine Tartrate | 86 | 25 |
| Pregabalin | Pregabalin | 85 | 23 |
| Oxcarbazepine | Oxcarbazepine | 84 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 22 |
| Atorvastatin Calcium | Atorvastatin Calcium | 79 | 21 |
| Emgality Pen | Galcanezumab-Gnlm | 78 | 13 |
| Ubrelvy | Ubrogepant | 72 | 19 |
| Belsomra | Suvorexant | 71 | 27 |
| Rizatriptan | Rizatriptan Benzoate | 71 | 20 |
| Aimovig Autoinjector | Erenumab-Aooe | 68 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 68 | 17 |
| Qulipta | Atogepant | 60 | 16 |
| Lacosamide | Lacosamide | 59 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 57 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 12 |
| Celecoxib | Celecoxib | 54 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 19 |
| Rytary | Carbidopa/Levodopa | 52 | 15 |
| Amantadine | Amantadine Hcl | 50 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 13 |
| Entacapone | Entacapone | 47 | suppressed |
| Losartan Potassium | Losartan Potassium | 46 | 14 |
| Meclizine Hcl | Meclizine Hcl | 44 | 13 |
| Eszopiclone | Eszopiclone | 43 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 42 | 12 |
| Trazodone Hcl | Trazodone Hcl | 41 | 12 |
| Verapamil Er | Verapamil Hcl | 41 | 12 |
| Botox | Onabotulinumtoxina | 40 | 16 |
| Gocovri | Amantadine Hcl | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Clonazepam | Clonazepam | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 32 | suppressed |
| Telmisartan | Telmisartan | 30 | suppressed |
| Zavzpret | Zavegepant Hcl | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Neupro | Rotigotine | 28 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 27 | 11 |
| Candesartan Cilexetil | Candesartan Cilexetil | 26 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 26 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 25 | suppressed |
| Xcopri | Cenobamate | 25 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 23 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Diazepam | Diazepam | 21 | 20 |
| Fycompa | Perampanel | 21 | suppressed |
| Lisinopril | Lisinopril | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 21 |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 19 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Austedo | Deutetrabenazine | 18 | suppressed |
| Furosemide | Furosemide | 17 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 15 | suppressed |
| Nourianz | Istradefylline | 15 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Briviact | Brivaracetam | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 11 | suppressed |
| Topamax | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,262.85 · 136 records | ABBVIE INC. | AJOVY, BOTOX, Briviact, EMGALITY, EPIDIOLEX, FANAPT, Fintepla, Gocovri, KISUNLA, LEQEMBI, NURTEC ODT, QULIPTA, Qelbree, REXULTI, Rystiggo, Symbravo, TYSABRI, Tascenso ODT, UBRELVY, UPLIZNA, VALTOCO, VRAYLAR, VUMERITY, VYALEV, VYVGART, ZAVZPRET, ZEMBRACE SYMTOUCH | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error